Psychedelic Therapy: Psilocybin, MDMA, and the Modern Renaissance

From the 1950s research that was banned, to the clinical trials that are bringing it back. Here's where psychedelic therapy actually stands.

In 1954, Abram Hoffer, a Canadian psychiatrist, published a paper in the British Columbia Medical Journal describing the use of psilocybin (the active compound in magic mushrooms) to treat alcoholism. His patient, a chronic alcoholic, had one psilocybin session and reportedly stopped drinking. The study had N=1 and no control group, which would make it publishable nowhere today. But it was the beginning of a genuine research program. Hoffer and his colleague Humphry Osmond — who later coined the term "psychedelic" (from the Greek psyche "mind" and deloun "to reveal") — ran a series of studies on psychedelics for addiction, schizophrenia, and depression through the 1950s and early 1960s.

The research was promising enough that major institutions got involved. The CIA ran its own secret psychedelic research program (MKUltra) out of paranoia that the Soviets had a mind-control drug. The National Institute of Mental Health funded studies at Harvard (Timothy Leary and Richard Alpert), NYU (Oliver Sachs, who later wrote Alexander's Way), and the Menlo Park VA hospital (where Stanislav Grof and Albert Hofmann worked). The consensus from these early studies was that psychedelics, used in therapeutic settings, could produce profound and lasting changes in personality, mood, and behavior.

Then the 1960s happened. Psychedelics escaped the lab and became counterculture staples. The research was shut down. In 1970, the Controlled Substances Act classified LSD, psilocybin, and DMT as Schedule I substances — defined as having "no currently accepted medical use and a high potential for abuse." The research that had been underway for two decades was effectively killed. It would take another 40 years for the field to restart.

The modern revival

The revival began at Johns Hopkins University, where researcher Roland Griffiths — who had actually conducted psilocybin research in the 1980s using psilocybin administered to rhesus monkeys — returned to human subjects research. His landmark 2006 study, published in Psychopharmacology, administered psilocybin to 36 volunteers in a carefully controlled setting with psychological support. The results: 79% of participants rated their psilocybin experience as among the five most spiritually significant experiences of their lives. For comparison, Griffiths had previously administered d-amphetamine to the same subjects, and 0% rated that experience as spiritually significant. The 2016 follow-up in JAMA Psychiatry compared psilocybin against ketamine in the same subjects and found psilocybin produced significantly higher mystical-type experiences and greater persistence of positive mood changes.

Griffiths's work established the modern template for psychedelic therapy: careful screening, psychological preparation, a structured dosing session with trained guides, and post-session integration. The drug isn't given alone — it's embedded in a therapeutic protocol. The model borrows from traditional ayahuasca ceremony practices (set and setting, experienced guides, retreat-like structure) but subjects everything to clinical research standards.

Parallel to Griffiths's psilocybin work, Rick Doblin's organization MAPS (Multidisciplinary Association for Psychedelic Studies, founded 1986) has been pursuing MDMA-assisted therapy for PTSD. MDMA (3,4-methylenedioxymethamphetamine, "ecstasy" or "molly") is technically an entactogen rather than a classic psychedelic — it increases empathy and reduces fear without producing the intense visual hallucinations of psilocybin or LSD. For PTSD therapy, this is actually a feature, not a bug. MDMA allows patients to process traumatic memories without the usual emotional flooding that makes trauma therapy so difficult. MAPS completed its Phase 2 trials in 2021 with results showing 67% of MDMA-assisted therapy patients no longer met PTSD criteria after treatment, compared to 30% in the placebo group. Phase 3 trials began in 2022, and a New Drug Application (NDA) was submitted to the FDA in 2024.

How it works: ego dissolution and the Default Mode Network

Robin Carhart-Harris's entropic brain hypothesis (2014) provides the leading mechanistic explanation for psychedelic therapy. Classic psychedelics (psilocybin, LSD, DMT, mescaline) activate 5-HT2A serotonin receptors, which disrupts the Default Mode Network — the brain system responsible for self-referential thinking, mind-wandering, and the sense of a fixed, continuous "self."

When the DMN is disrupted, the sense of a separate, bounded self dissolves. This is "ego dissolution" — one of the most reliably reported features of the psychedelic experience. Carhart-Harris's research shows that the degree of ego dissolution during a session strongly predicts the therapeutic benefit. The more the patient's rigid self-narrative dissolves, the more opportunity there is for new perspectives to emerge. A person trapped in a loop of self-criticism or trauma-related shame can't reframe their experience while their DMN is rigidly reinforcing the same patterns. Psychedelics temporarily break that rigidity, and in the space that opens, therapy can help construct a more adaptive narrative.

The legal landscape

As of 2026, the psychedelic legal landscape is fragmented and evolving. Key developments:

Decriminalization is not the same as legalization. Oregon and Colorado have created regulated psilocybin service centers — licensed facilities where trained facilitators guide patients through psilocybin sessions. This is a therapeutic model, not recreational legalization. You can't buy psilocybin at a dispensary like cannabis. The model is closer to supervised medical treatment.

Challenges and concerns

The psychedelic renaissance is real, but it faces real challenges. Commercialization is a major concern. Startups like Compass Pathways (backed by BlackRock) and Atai Life Sciences are pushing psychedelic drugs toward FDA approval, but the profit motive can conflict with the traditional emphasis on set, setting, and integration. A pill you swallow at home is easier to manufacture and sell than a 6-hour facilitated session with two trained guides, but it may also be less effective.

Safety screening is non-trivial. People with a personal or family history of psychosis should not take classic psychedelics — the risk of triggering a psychotic episode, while small, is real and potentially permanent. Screening tools exist, but they're not perfect. The 2020 psilocybin trial by the Heffter Research Institute found that 7% of participants experienced significant adverse effects, including anxiety, confusion, and one case of psychosis that required hospitalization.

Finally, the "one and done" model that some researchers propose — a single psychedelic session producing lasting therapeutic effects — may be overpromising. The most robust data (Griffiths's 2016 study) shows significant effects at 6 months, but longer-term follow-up data is limited. Psychedelic therapy may be a powerful tool, but it's unlikely to replace the hard, ongoing work that traditional therapy requires.

FAQ